- Home
- BTCT vs MBRX Comparison
BTCT vs MBRX Comparison
Compare BTCT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTCT | MBRX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Singapore | United States |
| Employees | 26 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 9.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BTCT | MBRX |
|---|---|---|
| Price | $0.52 | $0.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 319.0K | ★ 1.1M |
| Earning Date | 05-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $283.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.26 |
| 52 Week High | $3.12 | $7.98 |
Technical Indicators
Market Signals| Indicator | BTCT | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 25.18 | 15.98 |
| Support Level | N/A | N/A |
| Resistance Level | $1.21 | $0.57 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 1.12 | 9.67 |
Price Performance
Historical ComparisonAbout BTCT BTC Digital Ltd.
BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.